2-[3-[4-[3-(1,3-Dioxobenzo[de]isoquinolin-2-yl)propylamino]butylamino]propyl]benzo[de]isoquinoline-1,3-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 2-[3-[4-[3-(1,3-Dioxobenzo[de]isoquinolin-2-yl)propylamino]butylamino]propyl]benzo[de]isoquinoline-1,3-dione
• 化学式: C₃₄H₃₄N₄O₄
• 分子量: 562.7
• InChiKey: SBPCLIKVFRXJSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  42
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  98.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• BISNAPHTHALIMIDOPROPYL DERIVATIVE COMPOUNDS WITH ANTI-PARASITE AND ANTI-CANCER ACTIVITY
  申请人：Cordeiro Da Silva Anabela

  公开号：US20090062329A1

  公开（公告）日：2009-03-05

  The bisnaphthalimidopropyl derivatives with anti-parasitic and anti-cancer activity. Bisnaphthalimidopropyl derivatives (A) BNIPPut, BNIPDapen, BNIPDhex, BNIPDahep, BNIPDaoct, BNIPDanon, BNTPDadec, BNIPDadod, BNPDpta, BNIPDeta were synthesized in yields ranging from 50-70 and their cytotoxicity against colon cancer cells (CaCo-2) and the parasite Leishmania infantum determined using the MTT assay and by luciferase activity present in parasite, respectively. Cytotoxicity within CaCo-2 cells was manifested with IC 50 values between 0.3 and 22 m M after 48 h of compounds incubation. Against Leishmania infantum , IC 50 values were encompassed within a narrower concentration range of 0.39-2.09 m M, for pro-mastigote form, and between 5.24 and 17.42 m M, for axenic amastigote and between 2.43 and 9.52 m M, for intracellular amastigote forms. These compounds can be an alternative to the normal therapeutic in the fields below (A), could be a solution to the toxicity and resistance related to the compounds existent in the market. Point of diversity.

  这些双萘酰亚胺丙基衍生物具有抗寄生虫和抗癌活性。双萘酰亚胺丙基衍生物（A）BNIPPut、BNIPDapen、BNIPDhex、BNIPDahep、BNIPDaoct、BNIPDanon、BNTPDadec、BNIPDadod、BNPDpta、BNIPDeta的合成产率在50-70之间，并通过MTT测定和寄生虫Leishmania infantum中的荧光素酶活性评估它们对结肠癌细胞（CaCo-2）的细胞毒性。在48小时化合物孵育后，CaCo-2细胞内的细胞毒性表现为IC50值在0.3和22 m M之间。对于Leishmania infantum，IC50值在0.39-2.09 m M的较窄浓度范围内，适用于原鞭毛体形式，以及在5.24和17.42 m M之间，适用于离体无菌性无鞭毛体和在2.43和9.52 m M之间，适用于细胞内无鞭毛体形式。这些化合物可能是以下领域中常规治疗的替代品（A），可能是解决市场上现有化合物相关毒性和耐药性的解决方案。多样性的观点。
• US8350036B2
  申请人：——

  公开号：US8350036B2

  公开（公告）日：2013-01-08